Navigation Links
Anthera Announces Third Quarter 2010 Financial Report and Conference Call
Date:10/26/2010

HAYWARD, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will release its third quarter 2010 financial report after market close on Tuesday, November 2, 2010.  Anthera will host a conference call at 5 pm Eastern Time in conjunction with the release.Conference Call Access:Date:

November 2, 2010Time:

5:00 pm Eastern TimeDomestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

19111226To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291.  The conference ID for the replay is 19111226. The audio replay will be available until November 9, 2010.  This conference call will be webcast live and archived on Anthera's website until November 2, 2011, www.anthera.com.  

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BAFF, which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , Mar 01, 2017 Research and ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... 2016, provides drug pricing data and benchmarks in the global Acute ... clinical attributes of your competitor drugs and find out how the ...
(Date:3/1/2017)... -- The global  Intraoperative Neuromonitoring (IONM) market  is expected to reach ... Research, Inc. The intraoperative neuromonitoring market is anticipated to witness significant growth in ... in a wide spectrum of surgeries. Continue Reading ... ... ...
(Date:3/1/2017)... El mismo sistema se mostrará en el Congreso Europeo de Radiología (CER) en Viena. ... ... open MRI scanner - MROpen engineered and developed by Paramed in the ESC Cardiff ... Paramed Medical Systems ... Gales. El escáner se localizará en el nuevo centro del European Scanning Centre situado en ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... After a long period of indulging ... While juice cleanses and workouts top the detox categories, there is a rare yet ... The Kerry Gaynor Method’s Vital Lung Detox is an herbal-based formula designed to help ...
(Date:3/1/2017)... ... 01, 2017 , ... Look for a new collection of edible berry plants ... Star Roses and Plants is launching their new Bushel and Berry Collection , ... Collection makes growing fresh fruit simple with a variety of easy-to-grow, low-maintenance container berry ...
(Date:3/1/2017)... CA (PRWEB) , ... March 01, 2017 , ... Breast ... for the treatment of early stage breast cancer and where it fits in the ... & The Choices We Make .” The event brings together leading cancer and wellness ...
(Date:3/1/2017)... ... March 01, 2017 , ... Granite Peaks ... cancer screening rates by supporting the 80% by 2018 initiative, led by the ... the National Colorectal Cancer Roundtable (an organization co-founded by ACS and CDC). , ...
(Date:3/1/2017)... ... 2017 , ... “There is Comfort for the Soul”: a loving account of ... all-too-brief time together, and the soul-healing comfort provided by God’s presence in the face ... author, Jerie A. Tau, a dog-loving medical professional whose work takes her to remote ...
Breaking Medicine News(10 mins):